News

SARS-CoV-2 variants may escape monoclonal antibodies (mAbs) and antiviral drugs. This paper investigates differences in activity of mABs and antiviral drugs against newly emerging SARS-CoV-2 variants. To read more go to publications or access through the link https://www.mdpi.com/1999-4915/14/7/1374

This is a review paper where it is highlighted the main determinants of the emergence, epidemic response and available countermeasures of these three pandemics, and argued that such knowledge is paramount to prepare for the next pandemic. To read more about it go to publications or access through the link https://www.frontiersin.org/articles/10.3389/fmicb.2022.889643/full

In Italy, the pilot phase of the schools study of the European project “EuCARE: European cohorts of patients and schools to advance response to epidemics,” has started. To learn more see the interview Francesca Incardona gave to RA channel. Go to https://www.youtube.com/watch?v=sWKUdP_OOeU&t=6s.

To read more about it go to publications or access through the link https://www.mdpi.com/1660-4601/19/9/5384

The EuCARE session in the AREVIR meeting was held in Köln on 6 May 2022. In this session, the preliminary results of some of the WorkPackages of the project were presented.

Maruzio Zazzi presented recent results on the “Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies”

Francesca Incardona discussed How to best approach surveillance and evaluate the impact of NPIs in schools at the meeting organised by EU and ECDC

Suspected variant SARS-CoV-2 Omicron due to a negative result on the molecular test for the gene N found at the lab of the University of Tor Vergata.